Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.36 |
| ▸ | POLQ | O75417 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | PTP4A3 | O75365 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | TMPRSS4 | Q9NRS4 | 2/20 | 0.35 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4634616 | 0.83 | RAB9A (0.41) | RAB9ACYP1A2CYP2D6CYP2C19THRB | |
| SCHEMBL4634618 | 0.83 | RAB9A (0.41) | RAB9ACYP1A2CYP2D6CYP2C19THRB | |
| SCHEMBL162277 | 0.79 | RAB9A (0.40) | RAB9ACYP1A2CYP2D6CYP2C19THRB | |
| SCHEMBL29648862 | 0.79 | RAB9A (0.40) | RAB9ACYP1A2CYP2D6CYP2C19THRB | |
| SCHEMBL12947153 | 0.78 | IDO1 (0.42) | HCAR1MRGPRX4 | |
| SCHEMBL10905196 | 0.77 | THRB (0.38) | RAB9ACYP1A2CYP2D6CYP2C19THRB | |
| SCHEMBL14823831 | 0.76 | HSD17B3 (0.41) | RAB9ATHRBPKMMAPTHTT | |
| SCHEMBL12990386 | 0.76 | TSHR (0.55) | KDM4EGLATP53MAPTSMN1; SMN2 | |
| SCHEMBL12509626 | 0.76 | SMN1; SMN2 (0.38) | RAB9AKDM4EGLATP53MAPT | |
| SCHEMBL30562945 | 0.76 | RAB9A (0.36) | RAB9ACYP1A2CYP2D6CYP2C19THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130231327-A1 | Substituted Spiro-Amide Compounds | GRUENENTHAL GMBH (DE) | 2013-09-05 | — | — | US | disclosed |
| US-8455475-B2 | Substituted spiro-amide compounds | GRUENENTHAL GMBH (DE) | 2013-06-04 | — | — | US | disclosed |
| US-8455475-B2 | Substituted spiro-amide compounds | GRUENENTHAL GMBH (DE) | 2013-06-04 | — | — | US | disclosed |
| US-8378143-B2 | Methods of making Efavirens and intermediates thereof | APOTEX PHARMACHEM INC. (CA) | 2013-02-19 | — | — | US | disclosed |
| US-8236805-B2 | Substituted piperazines as CB1 antagonists | INTERVET INC. (US) | 2012-08-07 | — | — | US | disclosed |
| US-8236805-B2 | Substituted piperazines as CB1 antagonists | INTERVET INC. (US) | 2012-08-07 | — | — | US | disclosed |
| EP-2456773-A1 | METHODS OF MAKING EFAVIRENZ AND INTERMEDIATES THEREOF | Apotex Pharmachem Inc. (CA) | 2012-05-30 | — | — | EP | disclosed |
| US-20120095249-A1 | METHODS OF MAKING EFAVIRENS AND INTERMEDIATES THEREOF | APOTEX PHARMACHEM INC. (CA) | 2012-04-19 | — | — | US | disclosed |
| US-8080655-B2 | Methods of making efavirenz and intermediates thereof | APOTEX PHARMACHEM INC. (CA) | 2011-12-20 | — | — | US | disclosed |
| WO-2011009203-A1 | METHODS OF MAKING EFAVIRENZ AND INTERMEDIATES THEREOF | APOTEX PHARMACHEM INC. (CA) | 2011-01-27 | — | — | WO | disclosed |
| US-20100249095-A1 | Substituted Spiro-amide Compounds | GRUENENTHAL GMBH (DE) | 2010-09-30 | — | — | US | disclosed |
| US-7700597-B2 | Substituted piperazines as CB1 antagonists | SCHERING CORPORATION (US) | 2010-04-20 | — | — | US | disclosed |
| US-7700597-B2 | Substituted piperazines as CB1 antagonists | SCHERING CORPORATION (US) | 2010-04-20 | — | — | US | disclosed |
| US-20100029607-A1 | Substituted Piperazines as CB1 Antagonists | SCHERING CORPORATION | 2010-02-04 | — | — | US | disclosed |
| US-20100029607-A1 | Substituted Piperazines as CB1 Antagonists | SCHERING CORPORATION | 2010-02-04 | — | — | US | disclosed |
| CN-1106389-C | Efficient enantioselective addition reactions using organozinc reagents | MERCK & CO INC (US) | 2003-04-23 | — | — | CN | disclosed |
| CN-1255919-A | Efficient enantioselective addition reaction using organozinc reagent | MERCK & CO INC (US) | 2000-06-07 | — | — | CN | disclosed |
| EP-0981520-A1 | EFFICIENT ENANTIOSELECTIVE ADDITION REACTION USING AN ORGANOZINC REAGENT | Merck & Co., Inc. (US) | 2000-03-01 | — | — | EP | disclosed |
| US-6015926-A | ADDING DIALKYLZINC TO CHIRAL ADDITIVE, ADDING SECOND ADDITIVE TO FORM CHIRAL ZINC COMPLEX, MIXING WITH ORGANOMETALLIC REAGENT, REACTING WITH CARBONYL COMPOUND TO FORM DESIRED ALCOHOL | MERCK & CO., INC. (US) | 2000-01-18 | — | — | US | disclosed |
| WO-1998051676-A1 | EFFICIENT ENANTIOSELECTIVE ADDITION REACTION USING AN ORGANOZINC REAGENT | MERCK & CO., INC. (US) | 1998-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130231327-A1 | Substituted Spiro-Amide Compounds | BDKRB1, BDKRB2, REN | RAB9A 678/4885CYP1A2 3400/4885CYP2D6 1926/4885 |
| US-20120095249-A1 | METHODS OF MAKING EFAVIRENS AND INTERMEDIATES THEREOF | CYP2F1, CYP4F11, CYP4F3 | RAB9A 3664/4885CYP1A2 25/4885CYP2D6 10/4885 |
| US-20100029607-A1 | Substituted Piperazines as CB1 Antagonists | CNR1, CNR2, GPR119 | RAB9A 1346/4885CYP1A2 475/4885CYP2D6 1031/4885 |
| US-20100249095-A1 | Substituted Spiro-amide Compounds | BDKRB1, BDKRB2, REN | RAB9A 678/4885CYP1A2 3400/4885CYP2D6 1926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.